Restoration of estrogen responsiveness by blocking the HER-2/neu pathway

Lois Witters, Linda Engle, Allan Lipton

Research output: Contribution to journalArticlepeer-review

47 Scopus citations

Abstract

HER-2/neu gene amplification or protein overexpression is evident in 20-30% of primary breast cancers. Its amplification correlates with poor prognosis. There appears to be an association between HER-2/neu overexpression and estrogen independence. The MCF-7 human breast carcinoma cell line is estrogen-dependent and sensitive to the anti-estrogen, tamoxifen (TAM). This line, when transfected with the HER-2/neu gene, becomes estrogen-independent and resistant to TAM. Blockade of the HER-2/neu receptor with 1-5 nM of the humanized HER-2/neu antibody, Herceptin, restored estrogen, as well as TAM, sensitivity. These results suggest that Herceptin or similar drugs may restore estrogen sensitivity and the administration of a HER-2/neu inhibitor with an anti-estrogen to premenopausal patients should be considered.

Original languageEnglish (US)
Pages (from-to)1163-1166
Number of pages4
JournalOncology reports
Volume9
Issue number6
DOIs
StatePublished - Nov 2002

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Restoration of estrogen responsiveness by blocking the HER-2/neu pathway'. Together they form a unique fingerprint.

Cite this